Efficacy Assessment of Emergency Percutaneous Coronary Intervention (PCI) for Acute Myocardial Infarction (AMI)

  • Jiajuan Chen Taihe Hospital in Shiyan City, Affiliated Taihe Hospital of Hubei University of Medicine
  • Hezhong Zhu Taihe Hospital in Shiyan City, Affiliated Taihe Hospital of Hubei University of Medicine
  • Jing Xu Taihe Hospital in Shiyan City, Affiliated Taihe Hospital of Hubei University of Medicine
  • Zhen Gao Taihe Hospital in Shiyan City, Affiliated Taihe Hospital of Hubei University of Medicine
  • Fei Cheng Taihe Hospital in Shiyan City, Affiliated Taihe Hospital of Hubei University of Medicine
  • Yunjie Wei Taihe Hospital in Shiyan City, Affiliated Taihe Hospital of Hubei University of Medicine
DOI: https://doi.org/10.18686/aem.v10i2.190
Keywords: Acute Myocardial Infarction, Thrombolytic Therapy, Percutaneous Coronary Intervention

Abstract

Objective: To assess the clinic effect of percutaneous coronary intervention in the treatment of acute myocardial infarction. Methods: 90 patients with acute myocardial infarction in our hospital were chosen to be research objects and they were divided into two groups: control group and research group. Patients in control group were only treated by thrombolytic therapy while those in research group were further treated by percutaneous coronary intervention on the basis of this treatment. Result: The efficacy of research group was higher than that in control group. The incidence of adverse events was 4.44%, which is lower than that in control group. Conclusion: We should effectively apply percutaneous coronary intervention in treating acute myocardial infarction so as to improve the cardiac function of the patients. In addition, this treatment is safer and will lower the incidence of heart and renal failure.

References

[1] Li X, Jin G. A Clinic Observation on emergency Percutaneous Coronary Intervention and Tirofiban combination treatment for Acute Myocardial Infarction (in Chinese). Journal of Critical Care in Internal Medicine 2017; 23(4): 315–317.

[2] Buzure A. A clinic research on emergency Percuta-neous Coronary Intervention for Acute Myocardial Infarction (in Chinese). Contemporary Medicine 2017; 23(15): 104–105.

[3] Huang Y, Wang J. Comparison of clinic efficacy and safety between emergency percutaneous coronary intervention and intravenous thrombolysis therapy in the treatment of acute myocardial infarction (in Chinese). Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease 2016; 24(7): 154–155.

[4] Yu H. Clinic efficacy of Urokinase Thrombolysis in 72 patients with Acute Myocardial Infarction (in Chinese). Medical Journal of Chinese People’s Health 2018; 30(2): 156–158.

[5] Pan L. Effect of Ticagrelor combined with Reteplase Thrombolytic Therapy on left ventricular systolic function and NT-proBNP level in patients with Acute Myocardial Infarction (in Chinese). Medical Journal of Chinese People's Health 2018; 30(12): 8–10.

[6] Li T, Chen Y. Comparison of efficacy between In-travenous Thrombolysis and emergency Percutane-ous Coronary Intervention in treating elderly pa-tients with Acute Myocardial Infarction (in Chinese). The Journal of Medical Theory and Practice 2017; 30(13): 156–157.

[7] Wu E, Cao Y. Clinical efficacy of emergency Inter-vention Therapy and Intravenous Thrombolysis in patients with Acute Myocardial Infarction compli-cated with Prehospital Cardiac Arrest (in Chinese). Guide of China Medicine 2018; 16(22): 91–92.

[8] Kang H. Effect of psychological intervention on prognosis of emergency Coronary Intervention in Acute Myocardial Infarction (in Chinese). China Health Standard Management 2018; 9(20): 155–156.
Published
2021-08-16
Issue
Vol 10 No 2 (2021)
Section
Original Research Article

Copyright (c) 2021 Jiajuan Chen, Hezhong Zhu, Jing Xu, Zhen Gao, Fei Cheng, Yunjie Wei

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.